Business
Rakovina Therapeutics Congratulates Partner - Variational AI for Winning LifeSciencesBC’s 2025 Emerging Biotech Company of the Year Award
Award Recognition underscores the importance of AI-driven drug discoveryVANCOUVER, British Columbia, July 11, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therapies through AI-powered drug discovery proudly congratulates partner, Variational AI, on being honored as the 2025 Emerging Company of the Year – Biotech by Life Sciences BC. This prestigious award recognizes a Briti
About this update from Rakovina Therapeutics Inc
[{"type":"image","alt":"Rakovina Therapeutics Inc","displaySize":"","headline":null,"caption":"Rakovina Therapeutics Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":101,"url":"https://media.zenfs.com/en/globenewswire.com/5f38052c45a7c766c8843075311b5e6b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8pDE_lHFFxIFLy74uLNlBg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5f38052c45a7c766c8843075311b5e6b","width":300,"height":101}},"lazy":false},{"type":"text","content":"Award Recognition underscores the importance of AI-driven drug discovery","length":72,"tagName":"p"},{"type":"text","content":"VANCOUVER, British Columbia, July 11, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therapies through AI-powered drug discovery proudly congratulates partner, Variational AI, on being honored as the 2025 Emerging Company of the Year – Biotech by Life Sciences BC.","length":392,"tagName":"p"},{"type":"text","content":"This prestigious award recognizes a British Columbia-based biotechnology company demonstrating exceptional progress and achievement of key strategic milestones, attributes that reflect Variational AI’s impressive momentum and innovation in the field.","length":250,"tagName":"p"},{"type":"text","content":"Since entering into a partnership with Rakovina Therapeutics in September 2024, Variational AI has applied its Enki™ generative AI platform to accelerate the discovery of novel DNA damage response (DDR) kinase inhibitors. Most recently, the platform has been used to advance the KT-5000 series, the newest generation of synthetic small-molecule candidates targeting DDR pathways. This collaboration has produced multiple structurally novel compounds with favorable drug-like properties and activity in validated cancer cell lines. Early data suggest these candidates hold strong promise as brain-penetrant agents for difficult-to-treat tumors and represent a significant step forward in the Company’s AI-powered discovery pipeline.“We’re proud to see Variational AI recognized as Emerging Biotech Company of the Year,” said Jeffrey Bacha, Executive Chairman of Rakovina Therapeutics. “This award highlights the transformative role of AI in drug di...